Microbicide clinical trial adherence: Insights for introduction

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Woodsong, Cynthia ^a   MacQueen, Kathleen ^b   Amico, K Rivet ^c   Friedland, Barbara ^d   Gafos, Mitzy ^e   Mansoor, Leila ^f   Tolley, Elizabeth ^b   McCormack, Sheena ^e  

^a INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d POPULATION COUNCIL   (United States)

^e MRC CLINICAL TRIALS UNIT   (United Kingdom)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Clinical trial adherence; HIV prevention; Vaginal microbicides

Indexed keywords

MICROBICIDE; ANTIINFECTIVE AGENT;

ATTITUDE TO ILLNESS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG RETENTION; DRUG SAFETY; HEALTH CARE DELIVERY; HEALTH PRACTITIONER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PATIENT COUNSELING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK FACTOR; CLINICAL TRIAL ADHERENCE; FEMALE; HIV PREVENTION; INTRAVAGINAL DRUG ADMINISTRATION; MALE; STATISTICS; VAGINAL MICROBICIDES;

CLINICAL TRIAL ADHERENCE; HIV PREVENTION; VAGINAL MICROBICIDES;

ADMINISTRATION, INTRAVAGINAL; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE;

MLCS; MLOWN;

EID: 84879181231     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18505     Document Type: Review

References (54)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74.
2. United Nations Programme on HIV/AIDS (UNAIDS). Together we will end AIDS. 2012. Geneva, Switzerland: UNAIDS; 2012.
3. Tolley EE, Harrison PF, Goetghebeur E, Morrow K, Pool R, Taylor D, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav. 2010;14(5):1124-36.
4. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13-9.
5. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, et al. A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the microbicides development programme. PloS One. 2010;5(7):e11600.
6. Turner AN, De Kock AE, Meehan-Ritter A, Blanchard K, Sebola MH, Hoosen AA, et al. Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews. J Clin Epidemiol. 2009;62(7):759-65.
7. Muchomba FM, Gearing RE, Simoni JM, El-Bassel N. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syn. 2012;61(4):490-8.
8. Masse BR, Boily MC, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol. 2009;6:5.
9. Weiss HA, Wasserheit JN, Barnabas RV, Hayes RJ, Abu-Raddad LJ. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol. 2008;5:8.
10. Baeten J. A tale of two trials: how adherence is everything in PrEP. 2012 Conference on Retroviruses and Opportunistic Infections; 2012 Mar 5-8; Seattle, Washington; 2012.
11. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, et al. Assessing the accuracy of adherence and sexual behaviour data in the MDP301 vaginal microbicides trial using a mixed methods and triangulation model. PloS One. 2010;5(7):e11632.
12. Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS. 2012;7(6):542-8.
13. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41(3):285-97.
14. Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr infect dis rep. 2008;10(6):515-21.
15. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Inter Med. 2012;156(11):817-33.
16. Ferrer RA, Morrow KM, Fisher WA, Fisher JD. Toward an information-motivation- behavioral skills model of microbicide adherence in clinical trials. AIDS Care. 2010;22(8):997-1005.
17. Roberts ET, Matthews DD. HIV and chemoprophylaxis, the importance of considering social structures alongside biomedical and behavioral intervention. Soc Sci Med. 2012;75(9):1555-61.
18. Uwah C,Wright S. Socio-cultural identities, perceptions of sexuality/sexual behavior and cultural contexts as determinants of HIV and AIDS prevalence in Southern Africa. World J AIDS. 2012;2(1):17-23.
19. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol 9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360(9338):971-7.
20. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25(7):957-66.
21. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977-87.
22. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359(5):463-72.
23. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329-37.
24. van der Straten A, Montgomery ET, Hartmann M, Minnis A. Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rev. 2013;10(1):89-102.
25. Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17(1):284-97.
26. Wilson IB, Carter AE, Berg KM. Improving the self-report of HIV antiretroviral medication adherence: is the glass half full or half empty? Curr HIV/AIDS Rep. 2009;6(4):177-86.
27. Whitehead SJ, Kilmarx PH, Blanchard K, Manopaiboon C, Chaikummao S, Friedland B, et al. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS. 2006;20(17):2141-8.
28. Delius P, Glaser C. Sex, disease and stigma in South Africa: historial perspectives. J AIDS Res. 2005;4(1):29-36.
29. McGrath JW, Schumann DA. Cultural determinants of sexual risk behavior for AIDS among Baganda women. Med Anth Quart. 2009;6(2):153-61.
30. Allen CF, Desmond N, Chiduo B, Medard L, Lees SS, Vallely A, et al. Intravaginal and menstrual practices among women working in food and recreational facilities in Mwanza, Tanzania: implications for microbicide trials. AIDS Behav. 2010;14(5):1169-81.
31. MTN. Trial finds tenofovir gel safe for daily use and most women adhered to study regimens. [cited 2008 Feb 25]. Available from: http://www.mtnstopshiv. org/node/359.
32. Woodsong C, Alleman P, Musara P, Chandipwisa A, Chirenje M, Martinson F, et al. Preventive misconception as a motivation for participation and adherence in microbicide trials: evidence from female participants and male partners in Malawi and Zimbabwe. AIDS Behav. 2012;16(3):785-90.
33. Koo HP, Woodsong C, Dalberth BT, Viswanathan M, Simons-Rudolph A. Context of acceptability of topical microbicides: sexual relationships. J Soc Issues. 2005;61(1):67-93.
34. Morrow KM, Fava JL, Rosen RK, Vargas S, Barroso C, Christensen AL, et al. Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties. J Acquir Immune Defic Syndr. 2007;45(1):93-101.
35. Tolley EE, Eng E, Kohli R, Bentley ME, Mehendale S, Bunce A, et al. Examining the context of microbicide acceptability among married women and men in India. Cult Health Sex. 2006;8(4):351-69.
36. Montgomery CM, Gafos M, Lees S, Morar NS, Mweemba O, Ssali A, et al. Re-framing microbicide acceptability: findings from the MDP301 trial. Cult Health Sex. 2010;12(6):649-62.
37. Montgomery CM, Lees S, Stadler J, Morar NS, Ssali A, Mwanza B, et al. The role of partnership dynamics in determining the acceptability of condoms and microbicides. AIDS Care. 2008;20(6):733-40.
38. Green G, Pool R, Harrison S, Graham JH, Wilkinson J, Nyanzib S, et al. Female control of sexuality: illusion or reality? Use of vaginal products in South West Uganda. Soc Sci Med. 2001;52(4):585-98.
39. Woodsong C. Covert use of topical microbicides: implications for acceptability and use. Int Fam Plan Perspec. 2004;30(2):94-8.
40. Weaver M, Tolley EE, Tsui S, editors. Patterns of adherence in two phase III microbicide trials. Washington, DC.: Alliance for Microbicide Development and Family Health International; 2007.
41. van der Straten A, Shiboski S, Montgomery ET, Moore J, De Bruyn G, Ramjee G, et al. Patterns and predictors of adherence to diaphragm use in a phase III trial in sub-Saharan Africa: a trajectory analysis. J Acquir Immune Defic Syndr. 2009;50(4):419-26.
42. Raymond EG, Taylor D, Cates WJ, Tolley EE, Borasky D, Cancel A, et al. Pregnancy in effectiveness trials of HIV prevention agents. Sex Transmit Dis. 2007;34(12):1035-9.
43. Schreiber CA, Sammel M, Hillier SL, Barnhart K. A little bit pregnant: the challenges of diagnosing pregnancy in microbicide trials. Contraception. 2006;74:179-97.
44. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-22.
45. van der Straten A, Montgomery E, Mavedzenge S, Musara P, Cheng H, Lutnick A, Woodsong C. Preference between precoital and daily use of Duet and BufferGel in Zimbabwe. AIDS Behav. 2012;16(7):1799-807.
46. Nel AM, Mitchnick LB, Risha P, Muungo LT, Norick PM. Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women. J Womens Health (Larchmt). 2011;20(8):1207-14.
47. Brady M, McGroy E. Shaping the operations research agenda for antiretroviral-based prevention products for women: gels and rings. New York: Population Council; 2012.
48. Coly A, Gorbach PM. Microbicide acceptability research: recent findings and evolution across phases of product development. Curr Opin HIV AIDS. 2008;3(5):581-6.
49. Mantell JE, Myer L, Carballo-Dieguez A, Stein Z, Ramjee G, Morar NS, et al. Microbicide acceptability research: current approaches and future directions. Soc Sci Med. 2005;60(2):319-30.
50. Morrow KM, Fava JL, Rosen RK, Christensen AL, Vargas S, Barroso C. Willingness to use microbicides varies by race/ethnicity, experience with prevention products, and partner type. Health Psychol. 2007;26(6):777-86.
51. Mensch BS, van der Straten A, Katzen LL. Acceptability in microbicide and PrEP trials: current status and a reconceptualization. Curr opin HIV AIDS. 2012;7(6):534-41.
52. Gafos M, Mzimela M, Sukazi S, Pool R, Montgomery C, Elford J. Intravaginal insertion in KwaZulu-Natal: sexual practices and preferences in the context of microbicide gel use. Cult Health Sex. 2010;12(8):929-42.
53. Woodsong C, Alleman P. Sexual pleasure, gender power and microbicide acceptability in Zimbabwe and Malawi. AIDS Educat Preven. 2008;20(2):171-87.
54. Hoffman S, Morrow KM, Mantell JE, Rosen RK, Carballo-Dieguez A, Gai F. Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial. Arch Sex Behav. 2010;39(3):748-760. doi: 10.1007/s10508-009-9509-3.